Show simple item record

dc.contributor.authorKang, Sung Hyun
dc.contributor.authorChess-Williams, Russ
dc.contributor.authorAnoopkumar-Dukie, Shailendra
dc.contributor.authorMcDermott, Catherine
dc.date.accessioned2018-01-04T02:50:41Z
dc.date.available2018-01-04T02:50:41Z
dc.date.issued2015
dc.identifier.issn0028-1298
dc.identifier.doi10.1007/s00210-015-1092-7
dc.identifier.urihttp://hdl.handle.net/10072/100010
dc.description.abstractIntravesical mitomycin C (MMC) is commonly used to treat bladder cancer but is associated with local adverse effects. Here, we investigate the effects of MMC on release of urothelial mediators and production of inflammatory cytokines. Recovery and the effects of repeat treatment were also investigated. Urothelial cells were treated with MMC for 2 h at 37 °C. Immediately, 24 h and 7 days following MMC treatment, effects were assessed in terms of changes in ATP, acetylcholine and PGE2 release, and the presence of inflammatory cytokines and nitric oxide in incubation medium. Endpoints were also assessed 7 days after repeat MMC treatment. Immediately following MMC treatment at the clinical concentration (2 mg/mL), stretch-induced ATP release was significantly decreased, basal acetylcholine release was enhanced, while basal PGE2 was depressed and response to stretch increased. Twenty-four hours after treatment, basal acetylcholine was significantly increased ([MMC] ≥0.0002 mg/mL) and basal PGE2 enhanced (0.02 mg/mL). A 326-fold increase in interleukin-8 secretion and significant increase in nitric oxide release were also detected at 24 h. One week after single and repeat MMC treatment, urothelial ATP, acetylcholine and PGE2 had recovered while the increase in nitric oxide and interleukin-8 was still evident. These results indicate that urothelial mediator release is affected by MMC treatment with full recovery by 1 week. However, a concurrent increase in secretion of the inflammatory cytokine interleukin-8 and nitric oxide was also detected 24 h following treatment, which were still evident after the recovery period. These changes may play a role in the local adverse effects associated with intravesical MMC treatment.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofpagefrom781
dc.relation.ispartofpageto791
dc.relation.ispartofissue7
dc.relation.ispartofjournalNaunyn-Schmiedeberg's Archives of Pharmacology
dc.relation.ispartofvolume388
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences not elsewhere classified
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciences
dc.subject.fieldofresearchMedical Physiology
dc.subject.fieldofresearchcode111599
dc.subject.fieldofresearchcode1115
dc.subject.fieldofresearchcode1116
dc.titleRecovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorAnoopkumar-Dukie, Shailendra


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record